Enlivex Therapeutics Ltd. (ENLV) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Ness Ziona, Israel. 현재 CEO는 Oren Hershkovitz.
ENLV 을(를) 보유 IPO 날짜 2014-07-31, 71 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $19.93M.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
